Product: METTL3 Antibody
Catalog: DF12020
Description: Rabbit polyclonal antibody to METTL3
Application: WB IHC
Cited expt.: WB
Reactivity: Human, Mouse, Rat
Prediction: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Xenopus
Mol.Wt.: 65-70 kDa,95kDa; 64kD(Calculated).
Uniprot: Q86U44
RRID: AB_2844825

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Zebrafish(91%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Xenopus(82%)
Clonality:
Polyclonal
Specificity:
METTL3 Antibody detects endogenous levels of total METTL3.
RRID:
AB_2844825
Cite Format: Affinity Biosciences Cat# DF12020, RRID:AB_2844825.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

adoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase; IME4; M6A; Methyltransferase like protein 3; Methyltransferase-like protein 3; METTL3; mRNA (2'-O-methyladenosine-N(6)-)-methyltransferase; mRNA m(6)A methyltransferase; MT-A70; MTA70; MTA70_HUMAN; N6 adenosine methyltransferase 70 kDa subunit; N6-adenosine-methyltransferase 70 kDa subunit;

Immunogens

Immunogen:

A synthesized peptide derived from human METTL3

Uniprot:
Gene(ID):
Expression:
Q86U44 MTA70_HUMAN:

Widely expressed at low level. Expressed in spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes.

Sequence:
MSDTWSSIQAHKKQLDSLRERLQRRRKQDSGHLDLRNPEAALSPTFRSDSPVPTAPTSGGPKPSTASAVPELATDPELEKKLLHHLSDLALTLPTDAVSICLAISTPDAPATQDGVESLLQKFAAQELIEVKRGLLQDDAHPTLVTYADHSKLSAMMGAVAEKKGPGEVAGTVTGQKRRAEQDSTTVAAFASSLVSGLNSSASEPAKEPAKKSRKHAASDVDLEIESLLNQQSTKEQQSKKVSQEILELLNTTTAKEQSIVEKFRSRGRAQVQEFCDYGTKEECMKASDADRPCRKLHFRRIINKHTDESLGDCSFLNTCFHMDTCKYVHYEIDACMDSEAPGSKDHTPSQELALTQSVGGDSSADRLFPPQWICCDIRYLDVSILGKFAVVMADPPWDIHMELPYGTLTDDEMRRLNIPVLQDDGFLFLWVTGRAMELGRECLNLWGYERVDEIIWVKTNQLQRIIRTGRTGHWLNHGKEHCLVGVKGNPQGFNQGLDCDVIVAEVRSTSHKPDEIYGMIERLSPGTRKIELFGRPHNVQPNWITLGNQLDGIHLLDPDVVARFKQRYPDGIISKPKNL

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Zebrafish
91
Xenopus
82
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

The METTL3-METTL14 heterodimer forms a N6-methyltransferase complex that methylates adenosine residues at the N(6) position of some RNAs and regulates various processes such as the circadian clock, differentiation of embryonic and hematopoietic stem cells, cortical neurogenesis, response to DNA damage, differentiation of T-cells and primary miRNA processing. In the heterodimer formed with METTL14, METTL3 constitutes the catalytic core. N6-methyladenosine (m6A), which takes place at the 5'-[AG]GAC-3' consensus sites of some mRNAs, plays a role in mRNA stability, processing, translation efficiency and editing. M6A acts as a key regulator of mRNA stability: methylation is completed upon the release of mRNA into the nucleoplasm and promotes mRNA destabilization and degradation. In embryonic stem cells (ESCs), m6A methylation of mRNAs encoding key naive pluripotency-promoting transcripts results in transcript destabilization, promoting differentiation of ESCs (By similarity). M6A regulates the length of the circadian clock: acts as an early pace-setter in the circadian loop by putting mRNA production on a fast-track for facilitating nuclear processing, thereby providing an early point of control in setting the dynamics of the feedback loop (By similarity). M6A also regulates circadian regulation of hepatic lipid metabolism. M6A regulates spermatogonial differentiation and meiosis and is essential for male fertility and spermatogenesis (By similarity). Involved in the response to DNA damage: in response to ultraviolet irradiation, METTL3 rapidly catalyzes the formation of m6A on poly(A) transcripts at DNA damage sites, leading to the recruitment of POLK to DNA damage sites. M6A is also required for T-cell homeostasis and differentiation: m6A methylation of transcripts of SOCS family members (SOCS1, SOCS3 and CISH) in naive T-cells promotes mRNA destabilization and degradation, promoting T-cell differentiation (By similarity). Inhibits the type I interferon response by mediating m6A methylation of IFNB. M6A also takes place in other RNA molecules, such as primary miRNA (pri-miRNAs). Mediates m6A methylation of Xist RNA, thereby participating in random X inactivation: m6A methylation of Xist leads to target YTHDC1 reader on Xist and promote transcription repression activity of Xist. M6A also regulates cortical neurogenesis: m6A methylation of transcripts related to transcription factors, neural stem cells, the cell cycle and neuronal differentiation during brain development promotes their destabilization and decay, promoting differentiation of radial glial cells (By similarity). METTL3 mediates methylation of pri-miRNAs, marking them for recognition and processing by DGCR8. Acts as a positive regulator of mRNA translation independently of the methyltransferase activity: promotes translation by interacting with the translation initiation machinery in the cytoplasm. Its overexpression in a number of cancer cells suggests that it may participate to cancer cell proliferation by promoting mRNA translation.

PTMs:

Sumoylation inhibits the N6-adenosine-methyltransferase activity. Sumoylation does not affect subcellular location or interaction with METTL14. Desumoylated by SENP1.

Subcellular Location:

Nucleus. Nucleus speckle. Cytoplasm.
Note: Colocalizes with speckles in interphase nuclei, suggesting that it may be associated with nuclear pre-mRNA splicing components (PubMed:9409616). In response to ultraviolet irradiation, colocalizes to DNA damage sites however, it probably does not bind DNA but localizes in the vicinity of DNA damage sites (PubMed:28297716).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Widely expressed at low level. Expressed in spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes.

Family&Domains:

Gate loop 1 and gate loop 2 regions are adjacent to the S-adenosyl-L-homocysteine-binding site and display large conformational changes upon ligand-binding. They may play an important role in adenosine recognition. The interface loop contributes to the heterodimer interaction.

Belongs to the MT-A70-like family.

References

1). MiR-29a-3p Improves Acute Lung Injury by Reducing Alveolar Epithelial Cell PANoptosis. Aging and Disease, 2022 (PubMed: 35656115) [IF=7.0]

Application: WB    Species: Mouse    Sample: lung tissue

Figure 2. METTL3-mediated m6A modification stabilizes the expression of miR-29a-3p. (A) The level of total m6A in the lung tissue of ALI mouse model. (B) m6A RIP detects the m6A level of pri-miR-29a in the lung tissue of ALI mouse model. (C) RT-qPCR detection of METL3 expression in the lung tissue of ALI mouse model. (D) Western blot analysis for the expression of METTL3 in the lung tissue of ALI mouse model. (E) Western blot analysis for the expression of METTL3 in A549 cells after siRNA transfection. (F) RT-qPCR analysis for the level of miR-29a-3p in A549 cells after METTL3 siRNA transfection. *** p <0.001.

2). Inhibition of METTL3 promotes mesangial cell mitophagy and attenuates glomerular damage by alleviating FOSL1 m6A modifications via IGF2BP2-dependent mechanisms. Biochemical pharmacology, 2025 (PubMed: 40081768) [IF=5.3]

3). METTL3 contributes to slow transit constipation by regulating miR‐30b‐5p/PIK3R2/Akt/mTOR signaling cascade through DGCR8. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022 (PubMed: 36068012) [IF=3.7]

4). METTL3 Promotes Osteosarcoma Metastasis via an m6A-dependent Epigenetic Activity of CBX4. Frontiers in bioscience (Landmark edition), 2024 (PubMed: 38538251) [IF=3.3]

5). METTL3 Promotes the Growth and Invasion of Melanoma Cells by Regulating the lncRNA SNHG3/miR-330-5p Axis. Cell transplantation, 2023 (PubMed: 37606168) [IF=3.2]

Application: WB    Species: human    Sample:

Figure 1. Elevated expression of METTL3 is associated with poor survival in patients with melanoma. (A) TCGA analysis of the expression of METTL3 in 474 non-paired melanoma samples. (B) RT-qPCR analysis of the expression levels of METTL3 in 10 pair-matched melanoma tissue samples. (C, D) Western blot analysis of the expression of METTL3 in 10 pair-matched melanoma samples. (E) Kaplan–Meier analysis of the association of METTL3 expression with overall survival and tumor recurrence in patients with melanoma. GAPDH: glyceraldehyde-3-phosphate dehydrogenase; METTL3: methyltransferase 3; RT-qPCR: real-time quantitative polymerase chain reaction; TCGA: The Cancer Genome Atlas.

6). METTL3-Mediated m6A Modification of lncRNA MALAT1 Facilitates Prostate Cancer Growth by Activation of PI3K/AKT Signaling. Cell transplantation, 2022 (PubMed: 36073002) [IF=3.2]

Application: WB    Species: human    Sample: DU145 and 22RV1 cells

Figure 1. Upregulation of METTL3 is associated with tumor recurrence in patients with PCa. (A) TCGA analysis of the expression levels of METTL3 in 52 pair-matched and 484 non-paired PCa tissue samples. (B, C) qRT-PCR and Western blot analysis of the expression levels of METTL3 in 10 pair-matched PCa tissue samples. (D) TCGA cohort analysis of the association of METTL3 with the prognosis in PCa with patients. PCa: prostate cancer; qRT-PCR: quantitative real-time polymerase chain reaction.

7). METTL3/14 and IL‐17 signaling contribute to CEBPA‐DT enhanced oral cancer cisplatin resistance. ORAL DISEASES, 2023 (PubMed: 34807506) [IF=2.9]

8). Fear stress promotes glioma progression through inhibition of ferroptosis by enhancing FSP1 stability. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023 (PubMed: 36484954) [IF=2.8]

9). METTL3-Mediated m6A Modification of FMRP Drives Hepatocellular Carcinoma Progression and Indicates Poor Prognosis. Cancer biotherapy & radiopharmaceuticals, 2024 (PubMed: 39263746) [IF=2.4]

10). HIF-1α-induced upregulation of m6A reader IGF2BP1 facilitates peripheral nerve injury recovery by enhancing SLC7A11 mRNA stabilization. In vitro cellular & developmental biology. Animal, 2023 (PubMed: 37783915) [IF=1.5]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.